The Cobas AmpliPrep – Cobas TaqMan Real-Time Polymerase Chain Reaction Assay Fails To Detect Hepatitis C Virus RNA in Highly Viremic Genotype 4 Clinical Samples To the
The Cobas AmpliPrep – Cobas TaqMan Real-Time Polymerase Chain Reaction Assay Fails To Detect Hepatitis C Virus RNA in Highly Viremic Genotype 4 Clinical Samples To the
复制标题
Cobas AmpliPrep – Cobas TaqMan 实时聚合酶链反应检测未能检测到高病毒血症基因型 4 临床样本中的丙型肝炎病毒 RNA
DOI：
--
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
J. Ducos
中科院分区：
文献类型：
--
作者：
E. Tuaillon;A. Mondain;L. Ottomani;L. Roudière;P. Perney;M. Picot;F. Séguret;F. Blanc;D. Larrey;P. Van de Perre;J. Ducos
肝活检有5例出现亚大面积坏死。这六名患者中有五名接受了移植，除一名外，其余均存活下来。其中一例因发生致命性胆管炎而无法进行移植。综上所述，约20%的AIH患者在首发时就有低频症状。入院时较低的MELD评分(28分)、较严重的肝纤维化以及早期(在类固醇治疗后4天内)血清胆红素和INR的改善或稳定，可以确定那些可能对类固醇治疗有反应的患者，从而在没有LT的情况下存活。我们的观察需要进一步的证实，但如果得到证实，这样的分层策略可以优化存在LF的AIH患者的护理。
five had submassive necrosis on liver biopsy. Five of these six patients underwent transplantation and all but one survived. One could not undergo transplantation due to development of fatal cholangitis. In conclusion, about 20% of patients with AIH have LF at initial presentation. A lower MELD score at admission ( 28), more severe hepatic fibrosis, and an early (within 4 days of steroid therapy) improvement or stabilization in serum bilirubin and INR identify those who are likely to respond to steroid therapy, and thus survive without LT. Our observations need further corroboration, but if confirmed, such a stratification strategy could optimize care of patients with AIH who present with LF.